Larimar Therapeutics (LRMR) Stock Forecast & Price Target

Compare

708 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LRMR Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Larimar

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LRMR Stock 12 Month Forecast

Average Price Target

$21.40

▲(522.09%Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Larimar Therapeutics in the last 3 months. The average price target is $21.40 with a high forecast of $40.00 and a low forecast of $12.00. The average price target represents a 522.09% change from the last price of $3.44.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","11":"$11","21":"$21","31":"$31","41":"$41"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,11,21,31,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.88,5.735384615384615,8.59076923076923,11.446153846153845,14.30153846153846,17.156923076923075,20.01230769230769,22.867692307692305,25.72307692307692,28.578461538461536,31.43384615384615,34.28923076923077,37.144615384615385,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.88,4.304615384615385,5.729230769230769,7.153846153846154,8.57846153846154,10.003076923076922,11.427692307692308,12.852307692307694,14.276923076923076,15.701538461538462,17.126153846153844,18.55076923076923,19.975384615384616,{"y":21.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.88,3.581538461538462,4.283076923076923,4.984615384615385,5.686153846153847,6.3876923076923084,7.0892307692307694,7.790769230769231,8.492307692307694,9.193846153846156,9.895384615384618,10.596923076923078,11.298461538461538,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.24,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.32,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.91,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.27,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.74,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.87,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.84,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.03,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$40.00

Average Price Target$21.40

Lowest Price Target$12.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Samantha SemenkowCiti

Citi

$14

Buy

306.98%

Upside

Reiterated

07/08/25

Positive Outlook for Larimar Therapeutics: Promising Data on Nomlabofusp and Anticipated Catalysts Drive Buy Rating

Joori ParkLeerink Partners

Not Ranked

Leerink Partners

―

Buy

―

Reiterated

07/08/25

Promising Potential of Larimar Therapeutics' Nomlabofusp in Friedreich's Ataxia: A Buy Rating Justified

Yatin SunejaGuggenheim

Guggenheim

$26

Buy

655.81%

Upside

Reiterated

06/25/25

Larimar Therapeutics (LRMR) Gets a Buy from Guggenheim

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/24/25

Larimar Therapeutics (LRMR) Gets a Buy from Truist Financial

Laura ChicoWedbush

Wedbush

$17→$15

Buy

336.05%

Upside

Reiterated

06/24/25

Larimar Therapeutics price target lowered to $15 from $17 at WedbushLarimar Therapeutics price target lowered to $15 from $17 at Wedbush

Myles MinterWilliam Blair

William Blair

―

Buy

―

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL) and Larimar Therapeutics (NASDAQ: LRMR)

Catherine NovackJonesTrading

JonesTrading

$14→$12

Buy

248.84%

Upside

Reiterated

06/23/25

JonesTrading Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)

Cory Jubinville, PhDLifeSci Capital

LifeSci Capital

$40

Buy

1062.79%

Upside

Reiterated

06/23/25

Larimar Therapeutics: FDA Guidance Boosts Buy Rating Amid Promising Regulatory Progress

Jonathan WollebenCitizens JMP

Citizens JMP

$21

Buy

510.47%

Upside

Reiterated

04/23/25

Citizens JMP reiterates Market Outperform Rating on Larimar Therapeutics (LRMR)Citizens JMP analyst Jonathan Wolleben reiterated a Market Outperform rating and $21.00 price target on Larimar Therapeutics (NASDAQ: LRMR).

Joel BeattyRobert W. Baird

Robert W. Baird

$13→$10

Buy

190.70%

Upside

Reiterated

03/25/25

Larimar Therapeutics price target lowered to $10 from $13 at BairdLarimar Therapeutics price target lowered to $10 from $13 at Baird

Edward WhiteH.C. Wainwright

H.C. Wainwright

$15→$16

Buy

365.12%

Upside

Reiterated

03/25/25

Promising Outlook for Larimar Therapeutics: Buy Rating on Nomlabofusp's Potential in Treating Friedreich's Ataxia

Andreas ArgyridesOppenheimer

Oppenheimer

$26

Buy

655.81%

Upside

Reiterated

12/17/24

Oppenheimer Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Samantha SemenkowCiti

Citi

$14

Buy

306.98%

Upside

Reiterated

07/08/25

Positive Outlook for Larimar Therapeutics: Promising Data on Nomlabofusp and Anticipated Catalysts Drive Buy Rating

Joori ParkLeerink Partners

Not Ranked

Leerink Partners

―

Buy

―

Reiterated

07/08/25

Promising Potential of Larimar Therapeutics' Nomlabofusp in Friedreich's Ataxia: A Buy Rating Justified

Yatin SunejaGuggenheim

Guggenheim

$26

Buy

655.81%

Upside

Reiterated

06/25/25

Larimar Therapeutics (LRMR) Gets a Buy from Guggenheim

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/24/25

Larimar Therapeutics (LRMR) Gets a Buy from Truist Financial

Laura ChicoWedbush

Wedbush

$17→$15

Buy

336.05%

Upside

Reiterated

06/24/25

Larimar Therapeutics price target lowered to $15 from $17 at WedbushLarimar Therapeutics price target lowered to $15 from $17 at Wedbush

Myles MinterWilliam Blair

William Blair

―

Buy

―

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL) and Larimar Therapeutics (NASDAQ: LRMR)

Catherine NovackJonesTrading

JonesTrading

$14→$12

Buy

248.84%

Upside

Reiterated

06/23/25

JonesTrading Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)

Cory Jubinville, PhDLifeSci Capital

LifeSci Capital

$40

Buy

1062.79%

Upside

Reiterated

06/23/25

Larimar Therapeutics: FDA Guidance Boosts Buy Rating Amid Promising Regulatory Progress

Jonathan WollebenCitizens JMP

Citizens JMP

$21

Buy

510.47%

Upside

Reiterated

04/23/25

Joel BeattyRobert W. Baird

Robert W. Baird

$13→$10

Buy

190.70%

Upside

Reiterated

03/25/25

Larimar Therapeutics price target lowered to $10 from $13 at BairdLarimar Therapeutics price target lowered to $10 from $13 at Baird

Edward WhiteH.C. Wainwright

H.C. Wainwright

$15→$16

Buy

365.12%

Upside

Reiterated

03/25/25

Promising Outlook for Larimar Therapeutics: Buy Rating on Nomlabofusp's Potential in Treating Friedreich's Ataxia

Andreas ArgyridesOppenheimer

Oppenheimer

$26

Buy

655.81%

Upside

Reiterated

12/17/24

Oppenheimer Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Larimar Therapeutics

1 Month

xxx

Success Rate

6/9 ratings generated profit

Average Return

+4.36%

reiterated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +4.36% per trade.

3 Months

xxx

Success Rate

14/25 ratings generated profit

Average Return

+22.00%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 56.00% of your transactions generating a profit, with an average return of +22.00% per trade.

1 Year

Jonathan WollebenCitizens JMP

Success Rate

15/25 ratings generated profit

Average Return

+25.78%

reiterated a buy rating 3 months ago

Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +25.78% per trade.

2 Years

xxx

Success Rate

5/9 ratings generated profit

Average Return

-7.92%

reiterated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 55.56% of your transactions generating a profit, with an average return of -7.92% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LRMR Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LRMR has received 12 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. LRMR average Analyst price target in the past 3 months is 21.40.

Each month's total comprises the sum of three months' worth of ratings.

LRMR Financial Forecast

LRMR Earnings Forecast

Next quarter’s earnings estimate for LRMR is -$0.48 with a range of -$0.52 to -$0.39. The previous quarter’s EPS was -$0.46. LRMR beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.14% of the time in the same period. In the last calendar year LRMR has Preformed in-line its overall industry.

No data currently available

LRMR Sales Forecast

Next quarter’s sales forecast for LRMR is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. LRMR beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.09% of the time in the same period. In the last calendar year LRMR has Preformed in-line its overall industry.

LRMR Stock Forecast FAQ

What is LRMR’s average 12-month price target, according to analysts?

Based on analyst ratings, Larimar Therapeutics, Inc.’s 12-month average price target is 21.40.

What is LRMR’s upside potential, based on the analysts’ average price target?

Larimar Therapeutics, Inc. has 522.09% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is LRMR a Buy, Sell or Hold?

Larimar Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is Larimar Therapeutics, Inc.’s price target?

The average price target for Larimar Therapeutics, Inc. is 21.40. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $12.00. The average price target represents 522.09% Increase from the current price of $3.44.

What do analysts say about Larimar Therapeutics, Inc.?

Larimar Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of LRMR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Larimar Therapeutics (LRMR) Stock Forecast & Price Target

LRMR Analyst Ratings

LRMR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Larimar Therapeutics

LRMR Analyst Recommendation Trends

LRMR Financial Forecast

LRMR Earnings Forecast

LRMR Sales Forecast

LRMR Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts